Efficacy and Safety of ACURATE neo2 in Valve-in-Valve TAVI: A Prospective Single-Center Study
Open Access
- 2 July 2025
- journal article
- research article
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (13) , 4677
Abstract
Background/Objectives: Valve-in-valve (ViV) transcatheter aortic valve implantation (TAVI) is a key approach for treating degenerated surgical bioprosthetic valves. The ACURATE neo2 valve, with its advanced sealing technology and optimized coronary access, represents a promising solution for the challenges of ViV TAVI. This study evaluates the procedural and 30-day and 1-year follow-up outcomes of the ACURATE neo2 valve in ViV TAVI. Methods: This single-center, single-operator prospective study included patients with symptomatic bioprosthetic valve dysfunction, classified in New York Heart Association (NYHA) class III or IV, who underwent ViV TAVI with ACURATE neo2 at our center between July 2022 and February 2024. Outcomes were assessed using VARC-3 criteria. Results: Fifty-five patients (51% females, median (IQR) age 76 (8) years) were included. The technical success rate was 98.2%. No patients experienced in-hospital mortality, stroke, MI, bleeding, vascular complications, renal failure, or new pacemaker implantation. Three patients (5.5%) underwent elective chimney stenting for coronary protection. The postprocedural mean aortic gradient was 6.7 ± 1 mmHg, with a mean aortic valve area (AVA) of 2.0 ± 0.1 cm2. Over a median follow-up period of 1.2 years, no deaths (0%) were observed, heart failure hospitalization rate was 3.6%, and NYHA class improved to ≤II in 100% of patients. Conclusions: ACURATE neo2 demonstrated excellent technical success, sustained hemodynamic performance, and significant clinical improvement in ViV TAVI. The absence of major adverse events reinforces its safety, efficacy, and durability as a treatment for degenerated surgical bioprostheses.Keywords
All Related Versions
This publication has 31 references indexed in Scilit:
- Comparative analysis of percutaneous vs. surgical access in transfemoral TAVR: a propensity-matched cohort studyHellenic Journal of Cardiology, 2025
- Valve Academic Research Consortium 3: Updated Endpoint Definitions for Aortic Valve Clinical ResearchJACC, 2021
- Transfemoral implantation of the ACURATE neo prosthesis using a low-profile expandable introducer system: A multicenter registryInternational Journal of Cardiology, 2019
- Cerebral Embolic Protection During Transcatheter Aortic Valve Replacement Significantly Reduces Death and Stroke Compared With Unprotected ProceduresJACC: Cardiovascular Interventions, 2017
- Bioprosthetic Valve Fracture to Facilitate Transcatheter Valve-in-Valve ImplantationThe Annals of Thoracic Surgery, 2017
- Protection Against Cerebral Embolism During Transcatheter Aortic Valve ReplacementJACC, 2017
- Effect of a Cerebral Protection Device on Brain Lesions Following Transcatheter Aortic Valve Implantation in Patients With Severe Aortic StenosisJAMA, 2016
- Cracking the ring of Edwards Perimount bioprosthesis with ultrahigh pressure balloons prior to transcatheter valve in valve implantationInternational Journal of Cardiology, 2014
- Transcatheter Aortic Valve Implantation in Failed Bioprosthetic Surgical ValvesJAMA, 2014
- Transcatheter Aortic Valve Implantation for Failing Surgical Aortic Bioprosthetic ValveJACC: Cardiovascular Interventions, 2011